Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
Ganzel C, Sun Z, Baslan T, Zhang Y, Gönen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, Litzow M, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E.
Ganzel C, et al.
Leuk Res. 2022 Dec;123:106971. doi: 10.1016/j.leukres.2022.106971. Epub 2022 Oct 21.
Leuk Res. 2022.
PMID: 36332294
Free PMC article.
Clinical Trial.